Propanc Biopharma (NASDAQ:PPCB) Releases Earnings Results

Propanc Biopharma (NASDAQ:PPCB) announced its quarterly earnings results on Friday, September 25th. The company reported ($1.77) earnings per share for the quarter, reports.

Propanc Biopharma Price Performance

Shares of Propanc Biopharma stock traded down $0.01 on Monday, reaching $0.50. The company had a trading volume of 88,769 shares, compared to its average volume of 1,918,675. The firm has a market cap of $1.14 million, a price-to-earnings ratio of -0.02 and a beta of 3.53. The firm’s 50-day moving average price is $0.99 and its two-hundred day moving average price is $1.72. Propanc Biopharma has a 1 year low of $0.47 and a 1 year high of $52.50.

Propanc Biopharma announced that its board has initiated a stock repurchase plan on Thursday, June 11th that authorizes the company to repurchase $5.00 million in shares. This repurchase authorization authorizes the company to purchase up to 162.3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of Propanc Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 26th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

About Propanc Biopharma

Propanc Biopharma, Inc is a biotechnology company focused on developing novel treatments for solid tumors. The company’s research centers on the use of proenzymes—precursors to digestive enzymes—as a potential therapeutic approach for targeting cancer cells and limiting tumor growth, recurrence and metastasis.

Propanc’s lead product candidate is PRP, an investigational proenzyme therapy being developed primarily for cancers with a high risk of recurrence, including pancreatic, ovarian and colorectal cancers.